Browse the evidence

Plant-based meat alternatives may have a lower environmental footprint than feedlot beef but a higher footprint than pasture-raised beef, and their nutritional complexity is underestimated by reductionist formulation.

If you are choosing plant-based meats for environmental reasons, know that they are generally better than feedlot beef but may not be as good as pasture-raised beef. Focus on a balanced diet that includes diverse plant sources to maximize health benefits, rather than relying solely on processed alternatives.

Rural residents in Saudi Arabia have higher prevalence of diabetes, obesity, and hypertension compared to urban residents, challenging the assumption that urbanization is the sole driver of CVD risk.

Rural residents in Saudi Arabia face higher risks of diabetes, obesity, and hypertension than their urban counterparts. This is likely due to lifestyle changes associated with modernization. Public health efforts should target rural communities with specific interventions to promote healthy eating and physical activity.

GLP-1 receptor agonists (GLP-1RA) are associated with a disproportionate reporting signal for specific neoplasms, particularly medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and pancreatic neoplasms, whereas overall tumor risk is not significantly increased.

GLP-1 receptor agonists do not increase the overall risk of cancer, but they are associated with specific, high-magnitude signals for medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and pancreatic neoplasms. Clinicians should maintain vigilance, particularly when combining GLP-1RA with DPP4 inhibitors, which may further increase reporting rates for these specific tumors. The benefits of GLP-1RA for cardiovascular and metabolic health remain significant, but patients with a history of MTC or pancreatitis should be carefully evaluated.

Chronic periodontitis acts as a source of systemic inflammation and oral pathogens (e.g., P. gingivalis) that contribute to the development and progression of Alzheimer's disease via immune subversion and blood-brain barrier compromise.

Prioritize rigorous oral hygiene (brushing, flossing, regular dental checkups) not just for dental health, but as a preventive measure against cognitive decline. If you have chronic gum disease, treating it may help reduce systemic inflammation, which is a known risk factor for Alzheimer's disease.

Probiotic supplementation, particularly Lactobacillus species, reduces oral inflammation and may improve cognitive function in Alzheimer's patients by modulating the gut-brain axis and reducing pro-inflammatory cytokines.

Consider probiotic supplementation, particularly those containing Lactobacillus, as a potential adjunct to support oral health and cognitive function. While not a cure, they may help reduce inflammation and support the gut-brain axis.

High-glycemic load carbohydrates drive obesity through calorie-independent hormonal mechanisms (specifically insulin-mediated fat storage and reduced energy expenditure) rather than solely through excess caloric intake.

Focus on reducing the glycemic load of your diet by minimizing refined carbohydrates, sugars, and processed grains. This approach addresses the hormonal drivers of fat storage (insulin) and energy partitioning, rather than relying solely on calorie restriction which may trigger metabolic slowdown and hunger.

Mendelian randomization studies suggest that genetic predisposition to MASLD via impaired VLDL secretion (PNPLA3, TM6SF2) may lower plasma lipids and potentially reduce coronary artery disease risk, whereas other MASLD genes show weak or no association with CAD.

This is a mechanistic insight rather than a direct intervention. It suggests that the way some people develop liver fat (by not secreting VLDL efficiently) might paradoxically protect them from heart disease. This highlights the complexity of the liver-heart axis.

Obesity in older adults may preserve absolute skeletal muscle mass compared to lean peers due to increased mechanical loading from higher body weight, creating an 'obesity paradox' where higher BMI is associated with lower mortality risk despite impaired muscle quality.

For older adults, maintaining muscle mass is crucial for survival. While obesity is linked to health risks, it may paradoxically help preserve the amount of muscle you have because your body has to work harder to move your weight. However, this doesn't mean obesity is 'good' for muscle function, which often declines. Focus on preserving muscle through activity rather than just focusing on weight loss, as losing muscle mass is a bigger risk than having extra fat.

Exposure to environmental obesogens (e.g., BPA, PFAS, pesticides) during critical developmental windows programs long-term metabolic dysfunction by hijacking redox signaling (ROS) and endocrine pathways, leading to increased adiposity and insulin resistance later in life.

To mitigate the impact of obesogens, prioritize reducing exposure to environmental chemicals that disrupt hormonal and redox signaling. This includes choosing fresh foods over ultra-processed items (which may contain obesogenic additives or packaging leachates), filtering drinking water, and minimizing the use of plastics (especially for heating food) and harsh household cleaners. While diet and exercise remain important, recognizing the role of environmental factors suggests that reducing exposure to these chemicals is a critical, often overlooked component of obesity prevention.

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) is associated with a low incidence (1.18%) of psychiatric adverse events, including depression, anxiety, and suicidal ideation, with a small but significant number of fatal outcomes.

If you are taking semaglutide, liraglutide, or tirzepatide, be aware that mood changes like depression, anxiety, or suicidal thoughts are possible, though uncommon (approx 1%). Monitor your mental health closely. If you experience these symptoms, report them to your doctor immediately. Do not suffer in silence; early reporting helps manage safety risks.

Succinate signaling via the SUCNR1 receptor is required for strength gains from resistance training, as blocking this pathway compromises training-induced grip strength improvements despite enhancing endurance capacity.

For strength training, your body uses succinate signaling to build muscle and neural adaptations. You don't need to supplement succinate; just perform progressive resistance training. The paper suggests that if you were to block this specific pathway, you would lose strength gains, so ensure your training is consistent and progressive to naturally stimulate this mechanism.

Oral administration of the bis-lipidated GLP-1 receptor agonist MEDI7219 significantly reduces body weight and glucose excursions in a canine model of obesity and insulin resistance, demonstrating that peptide engineering and targeted delivery can overcome gastrointestinal barriers to achieve clinical efficacy.

This research validates a new class of oral GLP-1 drugs (like MEDI7219) that use specific engineering to survive digestion and absorb into the blood. In dogs, daily oral tablets successfully reduced weight and blood sugar. While human trials are not yet reported here, the mechanism suggests oral GLP-1s could eventually match injectables in efficacy while avoiding injections.

Older adults disproportionately consume lower-quality plant-based proteins at lunch compared to younger and middle-aged adults, who primarily consume animal-based proteins at the same meal.

At lunch, older adults tend to eat lower-quality plant proteins (like bread) compared to younger people who eat meat or fish. Since animal proteins are more effective at building muscle, try to swap some of your lunch carbohydrates for a high-quality protein source like eggs, yogurt, or lean meat to better support your muscles.

GLP-1 receptor agonist treatment is associated with a statistically significant increase in specific psychiatric adverse events, including nervousness, stress, eating disorders, insomnia, binge eating, fear of eating, and self-induced vomiting, with onset typically occurring within the first 30 days.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that psychiatric side effects are a recognized risk, not just a rare anecdote. Symptoms like nervousness, stress, insomnia, and changes in eating behavior (such as bingeing or fear of eating) can start within the first month of treatment. Because these reports are disproportionately high in the database, you should proactively monitor your mental health and mood, especially if you have a history of anxiety or eating disorders, and report any new or worsening symptoms to your prescriber immediately.

Rapid weight loss induced by GLP-1 receptor agonists (e.g., semaglutide) causes significant facial volume depletion and skin laxity, resulting in an aged appearance termed 'Ozempic face'.

If you are taking Ozempic or similar drugs, be aware that rapid weight loss can hollow out your face and make you look older. This is a known side effect. If it happens, consult a plastic surgeon about fillers or skin tightening to restore volume.

Facial volume loss from GLP-1 agonists can be effectively treated with dermal fillers, skin tightening techniques, and surgical interventions.

If your face looks hollow after weight loss, consult a plastic surgeon. Treatments like fillers, lasers, or facelifts can restore volume and tighten skin. Be prepared for the costs and recovery time.

Sex hormone-binding globulin (SHBG) acts as a potential mediator in the causal relationship between higher cardiorespiratory fitness and lower type 2 diabetes risk.

Higher fitness is linked to higher levels of SHBG, which is known to protect against type 2 diabetes. This suggests that improving fitness may work partly by optimizing your hormone binding profiles.

Semaglutide treatment reduces plasma levels of FABP4 and modulates neutrophil phenotype (increasing CD88, reducing CD11b-mediated adhesion), thereby attenuating prothrombotic and atherosclerotic mechanisms.

For patients with Type 2 Diabetes and obesity who are not controlled on oral medications, Semaglutide (0.5-1.0 mg weekly) not only aids weight loss but may also reduce specific cardiovascular risk markers like FABP4 and improve neutrophil behavior, potentially lowering atherosclerosis risk. This benefit is observed after 6 months of treatment.

Baseline metabolite levels (BCAA, tyrosine, betaine, choline) do not predict the magnitude of weight loss achieved after bariatric surgery or lifestyle interventions.

Your baseline blood levels of BCAA, tyrosine, betaine, or choline will not tell you how much weight you will lose after surgery or a diet program. While these markers might predict whether your diabetes remits, they do not predict the magnitude of weight loss.

Branched-chain amino acid (BCAA) dysregulation directly causes pro-arrhythmic effects, including action potential prolongation and calcium dysregulation, independent of structural cardiac changes.

If you have diabetes or obesity, your risk of dangerous heart rhythms may be linked to how your body processes specific amino acids (leucine, isoleucine, valine) found in protein. While you don't necessarily need to eliminate protein, focusing on dietary patterns that improve metabolic health, such as the Mediterranean diet, may help lower BCAA levels and reduce arrhythmia risk. Consult your doctor about your specific metabolic profile.

Sarcopenic obesity (high BMI with low lean body mass) is associated with increased risk of dose-limiting chemotherapy toxicity and adverse survival outcomes in esophageal cancer patients.

For esophageal cancer patients, body composition (lean muscle mass) is as important as BMI. Doctors should consider lean body mass-based dosing for chemotherapy to reduce toxicity, especially in patients with sarcopenic obesity.

In human visceral and subcutaneous adipose tissue, p38α (Mapk14) mRNA levels inversely correlate with Body Mass Index (BMI) and positively correlate with UCP1 expression.

Humans with higher BMI tend to have lower levels of p38α mRNA in their fat tissue, and this lower level is linked to lower levels of the fat-burning protein UCP1. This suggests that restoring p38α might not be the direct solution, as its role is complex (inhibitory in BAT), but it highlights a biomarker of reduced fat-burning capacity in obesity.

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

Bariatric surgery does not significantly reduce all-cause mortality compared to conventional medical therapy in severely obese T2DM patients over the long term, although it reduces specific macrovascular events.

While bariatric surgery significantly reduces heart attacks and strokes in severely obese diabetics, this specific analysis did not find a statistically significant reduction in overall death rates compared to medical therapy. The benefits are substantial in terms of preventing major cardiovascular events, even if overall mortality remains similar in this dataset.